Sun Set For US Eye-care Push With BromSite Approval

Sun Pharma has received FDA approval for its ophthalmology NDA, BromSite (0.075% bromfenac), the first such non-steroidal anti-inflammatory drug (NSAID ) cleared by the agency to prevent pain and treat inflammation in cataract surgery patients.

Sun Pharma has received FDA approval for its ophthalmology NDA, BromSite (0.075% bromfenac), the first such non-steroidal anti-inflammatory drug (NSAID ) cleared by the agency to prevent pain and treat inflammation in cataract surgery patients.

Scrip had earlier indicated how the BromSite approval could set the stage for a push in the ophthalmology segment...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Musculoskeletal

More from Therapeutic Category